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Introduction: Gitelman syndrome is an inherited autosomal recessive renal salt-wasting disorder. It presents with
variable clinical symptoms including muscle weakness and fatigue, and the diagnosis is based on metabolic
alkalosis, hypokalemia, hypomagnesemia and hypocalciuria. It is usually diagnosed incidentally in early adulthood.
There are rare cases of Gitelman syndrome presenting in early childhood; however, to the best of our knowledge it
has not previously been associated with delayed puberty.
Case presentation: A 17-year-old South Asian man with recurrent episodes of generalized muscle weakness,
fatigue and cramps from the age of two years was admitted for further workup. Before the age of 12 years, the
episodes had been mild, but they then got progressively worse. Other symptoms include polyuria, polydipsia,
nocturia, paresthesia and occasional watery diarrhea. He also had a history of short stature, poor weight gain and
delayed developmental landmarks. His family history was unremarkable except for the consanguineous marriage of
his parents. An examination revealed a thin and lean man with blood pressure of 95/60mmHg. His height and
weight were below the third percentile and his sexual development was at Tanner Stage II. Laboratory work
revealed serum sodium of 124mmol/L, potassium 2.4mmol/L, calcium 6.5mmol/L and magnesium of 1.2mg/dL. His
testosterone level was low (0.85ng/mL, normal for his age 2.67 to 10.12ng/mL) with normal levels of luteinizing
hormone and follicle-stimulating hormone. The sex hormone findings were attributed to delayed puberty. A
24-hour urinary analysis revealed decreased excretion of calcium (25.9mg/24 hours). Based on the findings of
hypokalemic metabolic alkalosis without hypertension, severe hypomagnesemia and hypocalciuria, a diagnosis of
Gitelman syndrome was made. Treatment was started with oral supplementation of potassium, magnesium and
calcium along with spironolactone and liberal salt intake.
Conclusion: Diagnosis of Gitelman syndrome is usually made incidentally during adolescence or early adulthood
based on clinical and biochemical findings. We report that Gitelman syndrome can present during the early
childhood years. If undiagnosed and untreated, it can lead to growth retardation and delayed puberty.Introduction
Gitelman syndrome (GS) is an inherited autosomal re-
cessive renal disorder [1]. It results from different inacti-
vation mutations in the gene SLC12A3 on chromosome
16q. This gene encodes the thiazide-sensitive sodium
chloride co-transporter channel in the distal convoluted
tubule (DCT) of the kidney. Alongside other renal salt-
wasting syndromes (Bartter syndrome), GS is considered
to be a rare cause of hypokalemic metabolic alkalosis.* Correspondence: farhan.raza@tuhs.temple.edu
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nesemia and hypocalciuria [2,3]. It presents with variable
clinical symptoms including muscle weakness and
cramps, fatigue, tetany, vomiting, diarrhea and abdom-
inal pain. It is usually diagnosed incidentally during ado-
lescence or early adulthood. We report a case of GS
presenting in early childhood years and the conse-
quences of delayed diagnosis and lack of treatment.Case presentation
A 17-year-old South Asian man was referred to our de-
partment for recurrent episodes of generalized muscled. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
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Hypokalemia was initially detected at the first episode
and he was treated for periodic hypokalemic paralysis.
Before the age of 12 years, these episodes were mild,
readily improved with ringer lactate and potassium
chloride by his treating physician and occurred only
twice a year. Beyond the age of 12 years, these episodes
gradually worsened in frequency and intensity to the
point that they were refractory to previously adminis-
tered therapies and sometimes required hospitalization.
His symptoms were aggravated by physical activity and
hot weather, and were associated with polyuria, polydipsia,
nocturia, paresthesias and occasional painless non-bloody
diarrhea. He denied the use of any medication, including
laxatives and diuretics. He also had a history of short stat-
ure and poor weight gain. His birth history was unremark-
able but developmental landmarks were delayed. There
was no family history of renal salt-wasting syndromes or
delayed puberty. However, his parents were first cousins.
An examination revealed a thin and lean, but well-
oriented adolescent with no acute distress. His height and
weight were below the third percentile (weight 30kg;
height 147cm). His blood pressure was 95/60mmHg with
orthostatic changes. His sexual development was at Tan-
ner Stage II.
Investigations at the admitting hospital revealed a nor-
mal leukocyte count, platelet count, hemoglobin level
and erythrocyte sedimentation rate. His urea level was
34mg/dL, creatinine 0.9mg/dL and random blood glu-
cose 105mg/dL. His estimated glomerular filtration rate
based on the Modification of Diet in Renal Disease for-
mula was 97.9ml/min per 1.73m2. His high blood urea
nitrogen level was attributed to mild dehydration due to
the hot weather. He was found to have metabolic alkal-
osis: pH 7.58, HCO3
- 33.5, base excess +7.6. His serum
electrolytes were as follows: sodium 124mmol/L, potas-
sium 2.4mmol/L, calcium 6.5mmol/L and phosphate
3.4mg/dL. His serum magnesium level was not checked
at that time. Serum albumin, creatine phosphokinase,
free thyroxin, thyroid-stimulating hormone and parathy-
roid hormone levels were normal.
He was provisionally diagnosed with periodic hypokal-
emic paralysis and hypocalcemia. Treatment was started
with potassium and calcium supplements. After one
month, he showed little improvement and he was referred
to our department for further evaluation.
Further laboratory tests revealed a low magnesium level
(1.2mg/dl) and decreased 24-hour urinary excretion of
calcium (25.9mg/24 h). Luteinizing hormone and follicle-
stimulating hormone levels were also normal. His level of
testosterone was low (0.85ng/mL, normal for his age 2.67
to 10.12ng/mL). Electrocardiography showed a normal
sinus rhythm and prolonged QT interval. No abnormality
was found on an abdominal X-ray, chest X-ray or brainmagnetic resonance imaging. A renal ultrasound revealed
a prominent pelvicalyceal system. An insulin tolerance test
showed normal cortisol and growth hormone response.
Based on the findings of hypokalemic metabolic alkal-
osis without hypertension, severe hypomagnesemia and
hypocalciuria, a diagnosis of GS was made. No organic
cause of hypogonadism was established and the sex hor-
mone findings were attributed to delayed puberty. Treat-
ment was started with oral supplementation of potassium,
magnesium and calcium along with spironolactone and
liberal salt intake. Our patient and his parents were also
counseled about delayed puberty.
A limitation to this case report was that the diagnosis
could not be ascertained with sequencing of the impli-
cated gene due to unavailability of genetic sequencing at
the presenting hospital (Jinnah Hospital Lahore, Pakistan).
Discussion
In 1966, Gitelman et al. described a familial disorder in
three adult female patients with occasional episodes of
muscle weakness and tetany. Neither growth retardation
nor polyuria was detected. Hypokalemia, hypomagnes-
emia and hypocalciuria were present [1]. This familial dis-
order was GS and diagnosis was based on these clinical
and biochemical findings.
The prevalence of GS is estimated at approximately 1
in 40,000 and, accordingly, the prevalence of people het-
erozygous for the condition is approximately 1% in Cau-
casian populations [2]. However, there is paucity of data
about the clinical variability and carrier rate in other
populations. GS usually presents after the age of six
years and mostly the diagnosis is made only in adult-
hood [2]. In our patient, the symptoms started at the age
of two years in the form of recurrent episodes of muscle
weakness. These were mild and were easily treated but
gradually became more frequent and increased in inten-
sity, especially after the age of 12 years.
As described before, we postulate that GS can present
in early childhood with milder symptoms [3] and be-
come fully symptomatic in adolescence. However, this is
the first case to the best of our knowledge in this par-
ticular ethnicity.
GS is an autosomal recessive trait. It is caused by mis-
sense mutations in the SLC12A3 gene (located on
chromosome 16q) that encodes the thiazide-sensitive so-
dium chloride co-transporter [2,4]. In SLC12A3, 172 dis-
tinct mutations have been described, leading to extreme
phenotype variability [5]. Female patients with the same
mutations are relatively asymptomatic compared with
their male counterparts. The nature and position of the
SLC12A3 mutation, combined with male gender, seem to
be a determinant factor in the severity of GS [6].
Defects in the thiazide-sensitive sodium chloride co-
transporter in the DCT impair sodium and chloride
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ing to mild volume contraction. This volume contraction
and increased sodium delivery to the macula densa acti-
vates the renin-angiotensin-aldosterone axis. Aldosterone
increases sodium reabsorption in the cortical collecting
duct and leads to increased secretion of potassium and
hydrogen ions. This causes hypokalemia and alkalosis [7].
Nijenhuis et al. demonstrated hypocalciuria and hypo-
magnesemia in mouse models for GS and chronic thiazide
diuretic use. Hypocalciuria was secondary to enhanced
passive calcium reabsorption in the proximal tubule and
hypomagnesemia was secondary to the downregulation of
magnesium channels (TRPM6) in the DCT [8].
Most patients present with muscle cramps, weakness,
paresthesias and episodes of tetany or paralysis. Almost
6% of patients experience hypokalemic paralysis, similar
to our patient [7,9]. Other symptoms include nocturia,
polydipsia, diarrhea, dizziness and salt craving. These
symptoms are attributed to the electrolyte and acid-base
abnormalities. The majority of patients also show arterial
hypotension. GS can sometimes cause short stature and
growth failures [2], but to the best of our knowledge, GS
has not previously been reported to cause delayed puberty.
We postulate that delayed puberty in our patient was
associated with GS, as there was no family history of
delayed puberty. The lack of genetic testing prevented us
from confirming whether delayed puberty was secondary
to the malnutrition or a new pathogenetic etiology.
Hypokalemia and hypomagnesemia lead to a prolonged
QT interval in more than 50% of patients with GS. How-
ever, cardiac arrhythmias have been described in far fewer
patients. Sudden cardiac death has been reported in a few
cases [10].
A diagnosis of GS is based on clinical findings and bio-
chemical abnormalities. Typical laboratory findings in-
clude hypokalemia, metabolic alkalosis, hypomagnesemia
and hypocalciuria. Alongside other renal salt-wasting syn-
dromes (such as Bartter syndrome), GS is considered to
be a rare cause of hypokalemic metabolic alkalosis. How-
ever, the distinguishing features of GS are hypomagnes-
emia and hypocalciuria.
Treatment is directed at correcting potassium and mag-
nesium depletion. It requires life-long supplementation
and liberal salt intake. Potassium supplementation is with
potassium chloride and potassium-sparing diuretics, in-
cluding amiloride and spironolactone. However, in hypo-
tensive patients, these drugs should be used with caution.
Hypomagnesemia is corrected with magnesium chloride
(magnesium sulfate or oxide are avoided to prevent diar-
rhea) [7,11].
Conclusion
GS can present as early as two years of age. It is an un-
common cause of hypokalemic metabolic alkalosis but,with a typical clinical presentation and biochemical find-
ings, it can be diagnosed. GS has a broad phenotypic vari-
ation but few severe forms have been described recently.
These severe forms mostly present in male patients and
have complications including growth retardation and
delayed puberty. It remains unclear if early diagnosis
and treatment may prevent these complications.
Antenatal diagnosis of GS is technically feasible but
not advised due to the good prognosis in the majority of
patients. Given the new findings of severe cases, identi-
fying these patients at an early age may help to prevent
complications. Also, the need for and/or benefit of car-
diac screening in these patients remain unclear.
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